Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2021) Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication. Expert Review of Vaccines 20:4, pages 449-460.
Read now
Read now
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Review of Vaccines 19:7, pages 661-686.
Read now
Read now
Articles from other publishers (18)
Dominika A. Kalkowska, Steven G. F. Wassilak, Eric Wiesen, Cara C. Burns, Mark A. Pallansch, Kamran Badizadegan & Kimberly M. Thompson. (2023) Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. Risk Analysis.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Steven G.F. Wassilak, Stephen L. Cochi & Kimberly M. Thompson. (2023) Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine 41, pages A136-A141.
Crossref
Crossref
Dominika A. Kalkowska, Arend Voorman, Mark A. Pallansch, Steven G.F. Wassilak, Stephen L. Cochi, Kamran Badizadegan & Kimberly M. Thompson. (2023) The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine 41, pages A12-A18.
Crossref
Crossref
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2023) Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Frontiers in Public Health 11.
Crossref
Crossref
Dominika A Kalkowska, Steven GF Wassilak, Eric Wiesen, Concepcion F Estivariz, Cara C Burns, Kamran Badizadegan & Kimberly M Thompson. (2023) Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation. Gates Open Research 7, pages 55.
Crossref
Crossref
Dominika A Kalkowska, Mark A Pallansch, Stephen L Cochi & Kimberly M Thompson. (2021) Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options. The Journal of Infectious Diseases 224:9, pages 1529-1538.
Crossref
Crossref
Kimberly M. Thompson. (2021) Modeling and Managing Poliovirus Risks: We are Where we are…. Risk Analysis 41:2, pages 223-228.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Amanda Wilkinson, Ananda S. Bandyopadhyay, Jennifer L. Konopka‐Anstadt, Cara C. Burns, M. Steven Oberste, Steven G. F. Wassilak, Kamran Badizadegan & Kimberly M. Thompson. (2020) Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Risk Analysis 41:2, pages 329-348.
Crossref
Crossref
Dominika A. Kalkowska & Kimberly M. Thompson. (2020) Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. Risk Analysis 41:2, pages 312-319.
Crossref
Crossref
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Analysis 41:2, pages 349-363.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Stephen L. Cochi, Stephanie D. Kovacs, Steven G. F. Wassilak & Kimberly M. Thompson. (2020) Updated Characterization of Post‐OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. Risk Analysis 41:2, pages 320-328.
Crossref
Crossref
Dominika A. Kalkowska, Richard Franka, Jeff Higgins, Stephanie D. Kovacs, Joseph C. Forbi, Steven G. F. Wassilak, Mark A. Pallansch & Kimberly M. Thompson. (2020) Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria. Risk Analysis 41:2, pages 289-302.
Crossref
Crossref
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Analysis 41:2, pages 229-247.
Crossref
Crossref
Dominika A. Kalkowska & Kimberly M. Thompson. (2020) Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan. Risk Analysis 41:2, pages 266-272.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Steven G. F. Wassilak, Stephen L. Cochi & Kimberly M. Thompson. (2020) Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. Risk Analysis 41:2, pages 248-265.
Crossref
Crossref
Yushuo Chen, Tianrui Yue & Zixiao Zhang. (2021) The Pathology of Poliomyelitis and the Vaccines and Nonvaccine Therapy. E3S Web of Conferences 308, pages 02018.
Crossref
Crossref
Ming Te Yeh, Erika Bujaki, Patrick T. Dolan, Matthew Smith, Rahnuma Wahid, John Konz, Amy J. Weiner, Ananda S. Bandyopadhyay, Pierre Van Damme, Ilse De Coster, Hilde Revets, Andrew Macadam & Raul Andino. (2020) Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host & Microbe 27:5, pages 736-751.e8.
Crossref
Crossref
D. A. Kalkowska, M. A. Pallansch & K. M. Thompson. (2019) Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiology and Infection 147.
Crossref
Crossref